Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM78A antibody, catalog no. 70R-9322

A synthetic peptide for use as a blocking control in assays to test for specificity of CSTF3 antibody, catalog no. 70R-4882

A synthetic peptide for use as a blocking control in assays to test for specificity of RNF34 antibody, catalog no. 70R-8469

A synthetic peptide for use as a blocking control in assays to test for specificity of TAC1 antibody, catalog no. 70R-9810

A synthetic peptide for use as a blocking control in assays to test for specificity of CPEB4 antibody, catalog no. 70R-4969

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF660 antibody, catalog no. 70R-8159

A synthetic peptide for use as a blocking control in assays to test for specificity of RASGEF1C antibody, catalog no. 70R-5807

A synthetic peptide for use as a blocking control in assays to test for specificity of PPIB antibody, catalog no. 70R-1863

A synthetic peptide for use as a blocking control in assays to test for specificity of HIST1H1E antibody, catalog no. 70R-2889

A synthetic peptide for use as a blocking control in assays to test for specificity of SKIV2L antibody, catalog no. 70R-4624

A synthetic peptide for use as a blocking control in assays to test for specificity of CES7 antibody, catalog no. 70R-5468

A synthetic peptide for use as a blocking control in assays to test for specificity of FDFT1 antibody, catalog no. 70R-1132

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF570 antibody, catalog no. 70R-8113

A synthetic peptide for use as a blocking control in assays to test for specificity of AS3MT antibody, catalog no. 70R-4474

A synthetic peptide for use as a blocking control in assays to test for specificity of PLDN antibody, catalog no. 70R-2857

A synthetic peptide for use as a blocking control in assays to test for specificity of C14orf180 antibody, catalog no. 70R-6428

A synthetic peptide for use as a blocking control in assays to test for specificity of LEMD2 antibody, catalog no. 70R-6307

A synthetic peptide for use as a blocking control in assays to test for specificity of TCP11 antibody, catalog no. 70R-3458

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF3F antibody, catalog no. 70R-10401

A synthetic peptide for use as a blocking control in assays to test for specificity of MSH4 antibody, catalog no. 70R-5617

A synthetic peptide for use as a blocking control in assays to test for specificity of PHLDA2 antibody, catalog no. 70R-6017

A synthetic peptide for use as a blocking control in assays to test for specificity of TRIM55 antibody, catalog no. 70R-2754

A synthetic peptide for use as a blocking control in assays to test for specificity of KIF1C antibody, catalog no. 70R-1611

A synthetic peptide for use as a blocking control in assays to test for specificity of LIPT1 antibody, catalog no. 70R-2759

A synthetic peptide for use as a blocking control in assays to test for specificity of FCN3 antibody, catalog no. 70R-5456

A synthetic peptide for use as a blocking control in assays to test for specificity of BTF3 antibody, catalog no. 20R-1189

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCD2 antibody, catalog no. 70R-6717

A synthetic peptide for use as a blocking control in assays to test for specificity of BRI3BP antibody, catalog no. 70R-7252

A synthetic peptide for use as a blocking control in assays to test for specificity of KLRA1 antibody, catalog no. 70R-5962

A synthetic peptide for use as a blocking control in assays to test for specificity of DDB2 antibody, catalog no. 70R-10002

A synthetic peptide for use as a blocking control in assays to test for specificity of DNAL1 antibody, catalog no. 70R-10420

A synthetic peptide for use as a blocking control in assays to test for specificity of LOC652559 antibody, catalog no. 70R-2981

A synthetic peptide for use as a blocking control in assays to test for specificity of Gja4 antibody, catalog no. 20R-1255

A synthetic peptide for use as a blocking control in assays to test for specificity of DSG2 antibody, catalog no. 70R-6105

A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp161 antibody, catalog no. 70R-7991

A synthetic peptide for use as a blocking control in assays to test for specificity of ME2 antibody, catalog no. 70R-2512

A synthetic peptide for use as a blocking control in assays to test for specificity of C1orf159 antibody, catalog no. 70R-7031

A synthetic peptide for use as a blocking control in assays to test for specificity of Mapk12 antibody, catalog no. 70R-9409

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCF3 antibody, catalog no. 70R-6278

HER-2/neu protein:
HER-2/neu (85-94) is an epitope from the extracellular region of Human Epidermal Growth Factor Receptor-2, receptor tyrosine kinase, also known as CD340, ERBB2 and proto-oncogene Neu. HER-2/neu contains a binding domain for HLA-A*02:01 molecule. It has been demonstrated that the over-expression of HER-2/neu plays an important role in the development and progression in primary breast cancer but also in ovarian colorectal and pancreatic adenocarcinoma. HER-2/neu has become an important biomarker and target of therapy for 30% of breast cancer patients.
Applications of HER-2/neu (85-94):
HER-2/neu (85-94) has shown its capacity to induce both cellular and humoral immune response in vivo. HER-2/neu (85-94) is used to analyze specific cytotoxic CD8 T cells responses, it has been demonstrated by ELISPOT analyses that the stimulation of cytotoxic T cells in PBMCs by HER-2/neu (85-94) produce IFN-γ against cancer cell expressing HLA-A*02:01 molecules and HER-2/neu.
It has been also demonstrated that HER-2/neu (85-94) is the single peptide of HER-2/neu which involve an increase frequency of cytotoxic CD8 T cells in the peripheral blood of breast cancer patients. HER-2/neu (85-94) is also used for vaccine development to treat diagenous rat from allied ALC cancer cells co-expressing HLA-A*02:01 and HER-2/neu.

antigen

CNP-53 is a Research Tool for the study of protein interactions, pharmacology and cell biology. It is an activator that interacts with Ligand Receptor and Cell Biology. CNP-53 is a peptide with a molecular weight of 5310.1 Da, which is purified to be 99% pure. This product is suitable for use in research as well as in clinical trials and has been shown to inhibit ion channels and high purity proteins.

Analog of the native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas.
The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity.
It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide.
Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).

Portion of Influenza NP

NY-ESO-1 (157-165) peptide – SLLMWITQC

Cysteine peptide (Ac RFAAKAA COOH) is used in combination with Lysinepeptide (Ac RFAACAA COOH) in the Direct Peptide Reactivity Assay (DPRA) test.
Direct Peptide Reactivity Assay is used in cosmetic applications for the characterization of the skin sensitizing potential of a substance, framed by OECD Guideline no 442.
The molecular initiating event (MIE) in skin sensitization is a binding between epidermal proteins and the sensitizing chemical substance. MIE is part of the adverse outcome pathway (AOP) of skin sensitization.
It is thanks to the properties of Lysine peptide and Cysteine peptide that the chemical binding will be able to take place, so these synthetic heptapeptides will mimic the reaction of a skin exposed to a substance.
Binding between nucleophilic proteins and electrophile substance will be measured by High Performance Liquid Chromatography (HPLC). Therefore, the decrease in Lysine peptide and Cysteine peptide levels will be a sign of sensitizing event. Depending on the rate of depletion, the sensitizing character of a molecule will be determined (see table at the bottom of the page).
In chemico DPRA test also has wider applications such as hazard classification in cosmetics, but also for pharmaceuticals and biocides. It is a good alternative to animal experimentation.

Peptide H-DRV^YIHPFHL-OH is a heavy labelled form of Angiotensin I peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

Portion of Influenza A

MOG(35-55) human corresponds to amino acids 35 to 55 of the human myelin oligodendrocyte glycoprotein (MOG). It can be used in multiple sclerosis research to induce experimental autoimmune encephalomyelitis (EAE) in mouse and rat models.

A synthetic peptide for use as a blocking control in assays to test for specificity of SLFN12 antibody, catalog no. 70R-4361